Show Summary Details
Page of

Proteomics and Biomarkers 

Proteomics and Biomarkers
Chapter:
Proteomics and Biomarkers
Author(s):

Gwenael Pottiez

, Jayme Wiederin

, and Pawel Ciborowski

DOI:
10.1093/med/9780195399349.003.0062
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 May 2019

Proteome, a term that was created from the combination of "protein" and "genome," refers to the entire set of proteins expressed by a genome, cell, or tissue under a specified set of conditions. Just as genomics refers to the study of genes or genomes, so proteomics refers to the study of proteins or proteomes. More specifically, proteomics is the global study of the expression, localizations, functions, and interactions of proteins in any biological system. Proteomics emerged in the mid-1990s as a separate scientific field due to a rapid advancement in analytical technologies that made possible the reliable identification of multiple proteins simultaneously from the same biological sample. A biomarker, broadly defined, is any identifiable feature that reflects quantitative changes in a biological system. Biomarkers can indicate changes relevant to any aspect of a biological process or disease. This chapter explores the use of proteins, identified through proteomic methods, as biomarkers in the study and clinical management of HIV-associated disease. The particular focus is HIV-associated central nervous system disease.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.